Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy + AG + Camrelizumab for Pancreatic Cancer
NCT06435260Phase 2
Key facts
- Status
- Recruiting
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Countries
- 1
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- camrelizumab
- Conditions
- pancreatic cancer (PC)
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in pancreatic cancer (PC), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: R0-resection rate. Started Aug 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Hypofractionated radiotherapy+Camrelizumab+chemotherapy
Hypofractionated radiotherapy followed by AG regimen chemotherapy plus camrelizumab immunotherapy
03
Who it enrols
Adults with borderline resectable or locally advanced pancreatic ductal adenocarcinoma or acinar cell carcinoma, ECOG 0-1, without distant metastasis.
04
Endpoints
Primary
R0-resection rate
Secondary
Surgical conversion rate
Tumor regression rate
Objective response rate
Disease control rate
Overall survival
Event Free Survival
Adverse events
Quality of life scores
Beyond the preview
Go deeper on NCT06435260.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435260.